Cadth 2015 c6 final exploring opportunities for collaboration across the spectrum of
•Download as PPTX, PDF•
1 like•157 views
This document summarizes the current state of pharmacy and drug policy decision making within the Nova Scotia Health Authority. It describes the formation and structure of the health authority, which consolidated several previous health districts. It discusses the Drug and Therapeutics Committee process for reviewing drugs and making formulary decisions across the health authority's four zones. The committee considers safety, efficacy, costs and stakeholder input when making recommendations. It also notes some challenges in aligning the hospital formulary with the provincial drug plan and getting buy-in for decisions from clinicians.
Report
Share
Report
Share
Recommended
Maureen smith patient submissionspresentation.m smith.nov2015
Maureen smith patient submissionspresentation.m smith.nov2015Canadian Organization for Rare Disorders
The document discusses Ontario's process for incorporating patient evidence into its drug review and funding decisions. It outlines how patient groups can submit evidence to the Committee to Evaluate Drugs to provide insight into the impact of diseases and treatments from a patient perspective. The CED considers clinical, economic and patient evidence in making funding recommendations to the Executive Officer. It provides guidance on submitting patient evidence through a standard template and ensuring submissions are received by posted deadlines.Rare Disease access issues 2015 v2
The document discusses challenges in accessing rare disease drugs in Canada. It notes that Canada approves only around half of orphan drugs approved in the US and EU. Several provinces have established specialized programs to review rare disease drugs on a case-by-case basis. The document advocates for a "lifecycle approach" where patients are engaged throughout the drug development and review process to improve access and appropriate use. This could include managed access programs combining early approval with ongoing data collection to expand access while managing costs and uncertainties.
Canada Market Access Briefing
The document provides an overview of the Canadian pharmaceutical market, highlighting several key trends that will affect pharmaceutical manufacturers. The Canadian market, while smaller than some other countries, still ranks among the top 10 globally in drug spending. Launching a drug in Canada can be profitable if manufacturers understand the specific nuances of the market, such as Canada's complex reimbursement system with both public and private insurance. Health technology assessments play an important role in reimbursement decisions. Manufacturers must tailor their reimbursement and launch strategies to the target payer market, whether public or private plans. Health economic evidence is also becoming increasingly important for market access, pricing, and contracting in Canada.
Sustaining Vietnam's HIV and AIDS Programs
To sustain funding for its HIV and AIDS programs, the Government of Vietnam has set a goal of covering up to 70% of ARVs by 2018. HFG is assisting Vietnam in managing this financial transition through a number of management, policy, and financing measures, related to sustainable ARV procurement.
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Canadian Organization for Rare Disorders
This document summarizes Pamela Gavin's presentation on an evidence-based approach to assuring value for orphan drugs at the CEPHT Conference in Toronto. It discusses the progress made since the 1983 Orphan Drug Act, including over 700 approved orphan drugs. It then introduces the NORD-Trio partnership, which aims to ensure adequate access to orphan drugs through a patient-centric technology platform that measures stakeholder performance, defines quality measures, and advocates for patients and high performance. Finally, it provides examples of how this partnership could study the hepatitis C treatment landscape using real-world data on outcomes, access, and affordability.Foster Gesten, Learning the ABCs of APCs
NASHP conference: Learning the ABCs of APCs and Medical Homes. Advance Primary Care (APC) or medical home models in both managed and fee for service delivery systems. Speakers will describe a variety of strategies that states are using to support primary care providers by connecting them to necessary resources including care coordination, public health and social services.
Drug Access Navigation - An Insider's Perspective
ODANO (Oncology Drug Access Navigators of Ontario) is a provincial organization that provides support and advocacy to help cancer patients access the medications they need. It has over 50 members across various regions of Ontario who help navigate public and private drug coverage plans and work with patients' treatment teams. The organization faces challenges with wait times for public drug plans and lack of direct communication with private insurers, and works on case studies to help patients receive adequate funding for their cancer treatments.
2017 Federally Facilitated Marketplaces: Implications for Pharmaceutical and ...
The Centers for Medicare & Medicaid Services released its 2017 guidance on the FFM and this PowerPoint highlights the most critical takeaway points for pharma and biotech manufacturers.
Recommended
Maureen smith patient submissionspresentation.m smith.nov2015
Maureen smith patient submissionspresentation.m smith.nov2015Canadian Organization for Rare Disorders
The document discusses Ontario's process for incorporating patient evidence into its drug review and funding decisions. It outlines how patient groups can submit evidence to the Committee to Evaluate Drugs to provide insight into the impact of diseases and treatments from a patient perspective. The CED considers clinical, economic and patient evidence in making funding recommendations to the Executive Officer. It provides guidance on submitting patient evidence through a standard template and ensuring submissions are received by posted deadlines.Rare Disease access issues 2015 v2
The document discusses challenges in accessing rare disease drugs in Canada. It notes that Canada approves only around half of orphan drugs approved in the US and EU. Several provinces have established specialized programs to review rare disease drugs on a case-by-case basis. The document advocates for a "lifecycle approach" where patients are engaged throughout the drug development and review process to improve access and appropriate use. This could include managed access programs combining early approval with ongoing data collection to expand access while managing costs and uncertainties.
Canada Market Access Briefing
The document provides an overview of the Canadian pharmaceutical market, highlighting several key trends that will affect pharmaceutical manufacturers. The Canadian market, while smaller than some other countries, still ranks among the top 10 globally in drug spending. Launching a drug in Canada can be profitable if manufacturers understand the specific nuances of the market, such as Canada's complex reimbursement system with both public and private insurance. Health technology assessments play an important role in reimbursement decisions. Manufacturers must tailor their reimbursement and launch strategies to the target payer market, whether public or private plans. Health economic evidence is also becoming increasingly important for market access, pricing, and contracting in Canada.
Sustaining Vietnam's HIV and AIDS Programs
To sustain funding for its HIV and AIDS programs, the Government of Vietnam has set a goal of covering up to 70% of ARVs by 2018. HFG is assisting Vietnam in managing this financial transition through a number of management, policy, and financing measures, related to sustainable ARV procurement.
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Canadian Organization for Rare Disorders
This document summarizes Pamela Gavin's presentation on an evidence-based approach to assuring value for orphan drugs at the CEPHT Conference in Toronto. It discusses the progress made since the 1983 Orphan Drug Act, including over 700 approved orphan drugs. It then introduces the NORD-Trio partnership, which aims to ensure adequate access to orphan drugs through a patient-centric technology platform that measures stakeholder performance, defines quality measures, and advocates for patients and high performance. Finally, it provides examples of how this partnership could study the hepatitis C treatment landscape using real-world data on outcomes, access, and affordability.Foster Gesten, Learning the ABCs of APCs
NASHP conference: Learning the ABCs of APCs and Medical Homes. Advance Primary Care (APC) or medical home models in both managed and fee for service delivery systems. Speakers will describe a variety of strategies that states are using to support primary care providers by connecting them to necessary resources including care coordination, public health and social services.
Drug Access Navigation - An Insider's Perspective
ODANO (Oncology Drug Access Navigators of Ontario) is a provincial organization that provides support and advocacy to help cancer patients access the medications they need. It has over 50 members across various regions of Ontario who help navigate public and private drug coverage plans and work with patients' treatment teams. The organization faces challenges with wait times for public drug plans and lack of direct communication with private insurers, and works on case studies to help patients receive adequate funding for their cancer treatments.
2017 Federally Facilitated Marketplaces: Implications for Pharmaceutical and ...
The Centers for Medicare & Medicaid Services released its 2017 guidance on the FFM and this PowerPoint highlights the most critical takeaway points for pharma and biotech manufacturers.
Pep and pr ep cranston
This document summarizes Massachusetts' efforts to make pre-exposure prophylaxis (PrEP) available to prevent HIV transmission. It discusses the state's comparable demographics and challenges to other states. It outlines strategies used, including procuring prevention agencies, distributing guidance on PrEP, defining service packages, and Medicaid demonstration project planning. Next steps include surveying provider demand, linking prevention providers to prescribers, and implementing data collection to support PrEP implementation.
2018 opioid epidemic and its effect on texas hospitals ppt
The document discusses the opioid epidemic's effect on Texas hospitals. It notes that in 2017 nearly 3,000 Texans died from drug overdoses, more than the population of many Texas cities and towns. The financial cost to Texas is $20 billion annually. Hospitals' costs for treating overdose patients in intensive care rose 60% from 2009 to 2015. The Texas Hospital Association developed voluntary opioid prescribing guidelines for emergency departments to curb overprescribing and addiction as emergency room visits and inpatient stays for opioid issues have increased substantially. The guidelines recommend limiting replacement prescriptions, prescribing opioids cautiously, and consulting prescription monitoring programs.
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationCanadian Cancer Survivor Network
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/SurvivornetcaWebinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients Canadian Cancer Survivor Network
At this webinar, Steve Sampson (Global Public Affairs) discusses how the upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money should always be the focus for government, but the need for cost-containment needs to be balanced with access to optimal healthcare innovation for patients.Cadth 2015 c6 panel collab formulary hospital-public plan - eric lun final
1. The document discusses collaboration opportunities and challenges across different levels of formulary decision making in British Columbia, including the BC Ministry of Health, regional health authorities, and public drug plans.
2. It outlines the BC Ministry of Health drug review process and notes the various drug review processes used by different organizations in BC. There are both similarities and differences between public drug plans and hospital/health authority processes that need to be recognized.
3. Opportunities for collaboration include improving medication continuity during care transitions, enhancing patient care quality between community and acute care, optimizing drug review efficiency, and reducing drug costs. Challenges include reconciling governance differences and ensuring understanding of each other's drug review processes.
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...Canadian Organization for Rare Disorders
This document discusses the challenges public payers face with expensive drugs for rare diseases. It outlines the formation of a working group between Alberta, British Columbia, and Ontario to explore evidence-based approaches. The working group identified major themes of communication, evidence, pricing, and access. Opportunities exist to improve communication with patients and clinicians, establish robust evidence standards, assess cost-effectiveness and affordability, and balance timely access with stakeholder accountability. The working group's goal is to develop sustainable, evidence-informed solutions that promote equity and transparency for rare disease patients.Private Insurance Plans - Do they have a future in Canada?
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Background to the role of private drug insurance plans in Canada
● Impact on access of recent developments in private insurance plan programs
● Future directions of private insurance in Canada
View the video: https://youtu.be/rik50CrMffY
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Examining Models for a National Pharmacare Program
Please share this slideshow with anyone who may be interested!
In this webinar:
● What has prompted the recent re-emergence of public calls for national pharmacare?
● What are Canadian health ministers doing to address this issue?
● What are some potential models for national pharmacare that are under discussion?
Contact the presenters:
● Bill Dempster - wdempster@3sixtypublicaffairs.com
● Gerry Jeffcott - gjeffcott@3sixtypublicaffairs.com
View the video: https://youtu.be/Eh3593x4aoI
2016-2017 APhA-ASP MRM Resolution
The document proposes a resolution for a regional meeting that would support licensed pharmacy interns transferring Schedule III, IV, and V controlled substance prescriptions between pharmacies under pharmacist supervision. Currently, only pharmacists can directly transfer such prescriptions. The resolution argues that interns are already permitted to transfer non-controlled prescriptions and perform other duties with appropriate safeguards, so allowing controlled substance transfers as well could expand their roles without compromising patient safety standards. No existing resolutions address this topic. The proposal was submitted by a student from Cedarville University School of Pharmacy.
How patient groups can have more say in the drug approval process
In this presentation, Bill Dempster and Johanne Chambers of 3Sixty Public Affairs walk through the different steps in bringing a new medicine through the regulatory review process, health technology assessment and funding, highlighting where patients can make a difference, and how their role is rapidly expanding.
Ehdi summit ppt
The Texas Early Hearing Detection and Intervention Program (TEHDI) was established in 1999 to require newborn hearing screenings and follow-up services. Over 400,000 babies are born in Texas each year, and 2-3 per 1,000 are born with hearing loss. TEHDI works to screen newborns and ensure those who do not pass are referred for diagnostic evaluation and early intervention services if needed. TEHDI receives funding from Medicaid, grants from the CDC and HRSA, and works to reduce the rate of loss to follow-up through outreach and education.
Access to Drugs for Rare Diseases in Canada - April 2014
The document discusses access to drugs for rare diseases in Canada. It notes that Canada currently has no orphan drug policy or definition of rare diseases, unlike the US and EU. As a result, Canadian patients have access to only about half of the orphan drugs approved in the US and EU. A new proposed Canadian orphan drug regulatory framework aims to align with international standards to promote drug development and patient access. It also discusses challenges for drug reimbursement in Canada given the high costs of rare disease drugs and limitations of current review processes. Lifecycle approaches and managed entry programs are proposed to help improve sustainable access.
FMCC 2016 Health Is Primary by Robert Phillips
This document summarizes the goals and strategies of an organization called Family Medicine for America's Health (FMAHealth). FMAHealth aims to strengthen primary care in America through seven core strategies, including ensuring everyone has a primary care provider, achieving the triple aim of better health, better care and lower costs, and moving payment models away from fee-for-service. To achieve these goals, FMAHealth has established six tactic teams focused on areas like practice redesign, workforce, technology, payment models, research and engagement.
Access to cancer drugs under pharmacare
The document outlines an ideal vision for a universal Pharmacare program in Canada with the following key elements: all Canadians would have prescription drug coverage through a national formulary with no copays or deductibles; all Health Canada approved drugs would be reimbursed; and the process for reviewing drugs' clinical effectiveness would be fully transparent. However, it also notes some challenges with implementing this vision, including uncertainty around timely access to new drugs given the lengthy review process, the need to account for provincial healthcare priorities in a national formulary, and insufficient public funding requiring alternative sources and mechanisms to ensure access to necessary medications like cancer drugs.
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
The document discusses discordance between recommendations from the pan-Canadian Oncology Drug Review (pERC) and provincial funding decisions for cancer drugs in Canada. It presents results from a survey of provincial drug funding decision-makers that identified several potential reasons for discordance, including differences in priorities, clinical evidence, and budget constraints between the levels. Challenges to alignment included issues with clinical trial evidence as well as pressure to expand access, while suggested solutions centered on strengthening consensus around treatment pathways and priorities nationally.
Rare disease caucus
This document summarizes key provisions in the FDA Safety and Innovation Act (FDASIA) related to rare diseases. It discusses how FDASIA provides expedited pathways for drug and device approval for serious or life-threatening rare diseases through accelerated approval and breakthrough therapy designation. It also covers provisions around external experts, patient-focused drug development, rare pediatric disease priority review vouchers, guidance development, and changes to humanitarian device exemptions. The overall goal of these FDASIA provisions is to facilitate and encourage development of new therapies for rare and pediatric rare diseases.
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
The document discusses Canada's orphan drug regulatory framework and opportunities to improve access to rare disease drugs across Canada. It advocates for a life-cycle approach and managed access schemes where drugs are approved with evidence collection requirements. Traditional health technology assessment limits orphan drug access by rejecting drugs that are not cost-effective based on small clinical trials. The document recommends performance-based managed access programs with national guidelines and risk-sharing between provinces, patients, and companies to improve access while collecting long-term evidence on benefits, harms, and costs.STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
A Rare International Dialogue (Saturday May 11, 2019)
Ethnic and Diversity Issues
Inclusion in Clinical Trials - Jeff Keefer, IQVIA
How Will My Organization Absorb the Influx of New Patients? – Telehealth Cras...
How Will My Organization Absorb the Influx of New Patients? – Telehealth Cras...Epstein Becker Green
The implementation of the Affordable Care Act (“ACA”) has forced U.S. health care organizations to think about how best to position themselves to take advantage of such a massive change. It has been estimated that the ACA will expand coverage to approximately 32 million individuals lawfully present in the United States. At the same time, the United States’ rapidly increasing aging population will account for an additional 15 more million seniors covered by Medicare. This incredible influx of elderly and newly insured patients is forcing an already overly burdened U.S. health care system to utilize and implement policies to adequately handle this expanded patient population. But how will health care organizations absorb this radical increase in potential patients? Many are exploring telehealth/telemedicine options as an integral component of their treatment paradigm. They also need to address where the additional health care professionals will come from if the United States is not producing sufficient numbers.
In the final installment of EBG’s Telehealth Crash Course series, we will explore the potential health care immigration issues that employers should be aware of, as well as immigrant options that are available to help health care organizations recruit the foreign talent required to keep pace with a changing landscape.
Epstein Becker Green Webinar - Presented by Kimberly N. Grant
http://www.ebglaw.com/kimberly-n-grant/events/how-will-my-organization-absorb-the-influx-of-new-patients-telehealth-crash-course-webinar-series/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.Do States Like Telehealth? – Telehealth Crash Course Webinar Series
Telehealth has gone mainstream. As technology becomes more sophisticated and clinicians find innovative ways to provide services, the various applications of telehealth are taking on new dimensions. The trend toward telehealth is being driven by employers, private insurers, clinicians, and technology companies. The trend notwithstanding, serious legal and regulatory issues remain and will be a barrier to the wider adoption of telehealth. With the significant attention that recent litigation and enforcement activities in certain states have received, many view state laws and policies as the biggest impediment to the wider adoption of telehealth.
In the second installment of EBG’s Telehealth Crash Course series, we will discuss recent legal and regulatory developments in the states related to telehealth and the various initiatives underway to facilitate greater adoption of telehealth. Additionally, we will address issues such as multistate provider licensure, scope of practice, prescribing, and recently introduced state telehealth-related bills.
Epstein Becker Green Webinar - Presented by Rene Quashie on 9/15/2015.
http://www.ebglaw.com/ren%C3%A9-y-quashie/events/do-states-like-telehealth-telehealth-crash-course-webinar-series/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
Cadth 2015 c5 2. lacaze cadth symposium 2015 powerpoint
MICYRN is a Canadian non-profit organization established in 2011 to reduce barriers and duplication of effort in multi-jurisdictional pediatric research, particularly for rare diseases. Rare diseases affect over 2.7 million Canadians but each affects fewer than 2000 individuals. MICYRN works to improve diagnosis of rare diseases and develop new therapies through national research networks and collaborating in international research initiatives. MICYRN also supports patient registries and clinical trials infrastructure to study rare diseases and determine drug safety and effectiveness in children through its research informatics platform and partnerships with health organizations and industry.
Cadth 2015 c5 4. harkins.cadth.symposium.2015
1) The document discusses the journey of patient advocate Kirsten Harkins and her son Nicklas who was diagnosed with MPS I.
2) It describes some of the early challenges in advocating for funding and access to treatments for rare diseases in Canada.
3) Key to success has been collaboration between patient advocacy groups, health ministries, and other stakeholders to work towards more meaningful patient involvement in research, treatment evaluation, and healthcare policy decisions impacting rare disease patients.
More Related Content
What's hot
Pep and pr ep cranston
This document summarizes Massachusetts' efforts to make pre-exposure prophylaxis (PrEP) available to prevent HIV transmission. It discusses the state's comparable demographics and challenges to other states. It outlines strategies used, including procuring prevention agencies, distributing guidance on PrEP, defining service packages, and Medicaid demonstration project planning. Next steps include surveying provider demand, linking prevention providers to prescribers, and implementing data collection to support PrEP implementation.
2018 opioid epidemic and its effect on texas hospitals ppt
The document discusses the opioid epidemic's effect on Texas hospitals. It notes that in 2017 nearly 3,000 Texans died from drug overdoses, more than the population of many Texas cities and towns. The financial cost to Texas is $20 billion annually. Hospitals' costs for treating overdose patients in intensive care rose 60% from 2009 to 2015. The Texas Hospital Association developed voluntary opioid prescribing guidelines for emergency departments to curb overprescribing and addiction as emergency room visits and inpatient stays for opioid issues have increased substantially. The guidelines recommend limiting replacement prescriptions, prescribing opioids cautiously, and consulting prescription monitoring programs.
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and InnovationCanadian Cancer Survivor Network
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● A discussion on the Canadian public and private drug access environment
● A moderated panel on the broader access and innovation context, featuring an update on international access to innovative therapies, patient support programs, and innovative pathways for access to treatments
View the video:
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/SurvivornetcaWebinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients Canadian Cancer Survivor Network
At this webinar, Steve Sampson (Global Public Affairs) discusses how the upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money should always be the focus for government, but the need for cost-containment needs to be balanced with access to optimal healthcare innovation for patients.Cadth 2015 c6 panel collab formulary hospital-public plan - eric lun final
1. The document discusses collaboration opportunities and challenges across different levels of formulary decision making in British Columbia, including the BC Ministry of Health, regional health authorities, and public drug plans.
2. It outlines the BC Ministry of Health drug review process and notes the various drug review processes used by different organizations in BC. There are both similarities and differences between public drug plans and hospital/health authority processes that need to be recognized.
3. Opportunities for collaboration include improving medication continuity during care transitions, enhancing patient care quality between community and acute care, optimizing drug review efficiency, and reducing drug costs. Challenges include reconciling governance differences and ensuring understanding of each other's drug review processes.
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...Canadian Organization for Rare Disorders
This document discusses the challenges public payers face with expensive drugs for rare diseases. It outlines the formation of a working group between Alberta, British Columbia, and Ontario to explore evidence-based approaches. The working group identified major themes of communication, evidence, pricing, and access. Opportunities exist to improve communication with patients and clinicians, establish robust evidence standards, assess cost-effectiveness and affordability, and balance timely access with stakeholder accountability. The working group's goal is to develop sustainable, evidence-informed solutions that promote equity and transparency for rare disease patients.Private Insurance Plans - Do they have a future in Canada?
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Background to the role of private drug insurance plans in Canada
● Impact on access of recent developments in private insurance plan programs
● Future directions of private insurance in Canada
View the video: https://youtu.be/rik50CrMffY
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Examining Models for a National Pharmacare Program
Please share this slideshow with anyone who may be interested!
In this webinar:
● What has prompted the recent re-emergence of public calls for national pharmacare?
● What are Canadian health ministers doing to address this issue?
● What are some potential models for national pharmacare that are under discussion?
Contact the presenters:
● Bill Dempster - wdempster@3sixtypublicaffairs.com
● Gerry Jeffcott - gjeffcott@3sixtypublicaffairs.com
View the video: https://youtu.be/Eh3593x4aoI
2016-2017 APhA-ASP MRM Resolution
The document proposes a resolution for a regional meeting that would support licensed pharmacy interns transferring Schedule III, IV, and V controlled substance prescriptions between pharmacies under pharmacist supervision. Currently, only pharmacists can directly transfer such prescriptions. The resolution argues that interns are already permitted to transfer non-controlled prescriptions and perform other duties with appropriate safeguards, so allowing controlled substance transfers as well could expand their roles without compromising patient safety standards. No existing resolutions address this topic. The proposal was submitted by a student from Cedarville University School of Pharmacy.
How patient groups can have more say in the drug approval process
In this presentation, Bill Dempster and Johanne Chambers of 3Sixty Public Affairs walk through the different steps in bringing a new medicine through the regulatory review process, health technology assessment and funding, highlighting where patients can make a difference, and how their role is rapidly expanding.
Ehdi summit ppt
The Texas Early Hearing Detection and Intervention Program (TEHDI) was established in 1999 to require newborn hearing screenings and follow-up services. Over 400,000 babies are born in Texas each year, and 2-3 per 1,000 are born with hearing loss. TEHDI works to screen newborns and ensure those who do not pass are referred for diagnostic evaluation and early intervention services if needed. TEHDI receives funding from Medicaid, grants from the CDC and HRSA, and works to reduce the rate of loss to follow-up through outreach and education.
Access to Drugs for Rare Diseases in Canada - April 2014
The document discusses access to drugs for rare diseases in Canada. It notes that Canada currently has no orphan drug policy or definition of rare diseases, unlike the US and EU. As a result, Canadian patients have access to only about half of the orphan drugs approved in the US and EU. A new proposed Canadian orphan drug regulatory framework aims to align with international standards to promote drug development and patient access. It also discusses challenges for drug reimbursement in Canada given the high costs of rare disease drugs and limitations of current review processes. Lifecycle approaches and managed entry programs are proposed to help improve sustainable access.
FMCC 2016 Health Is Primary by Robert Phillips
This document summarizes the goals and strategies of an organization called Family Medicine for America's Health (FMAHealth). FMAHealth aims to strengthen primary care in America through seven core strategies, including ensuring everyone has a primary care provider, achieving the triple aim of better health, better care and lower costs, and moving payment models away from fee-for-service. To achieve these goals, FMAHealth has established six tactic teams focused on areas like practice redesign, workforce, technology, payment models, research and engagement.
Access to cancer drugs under pharmacare
The document outlines an ideal vision for a universal Pharmacare program in Canada with the following key elements: all Canadians would have prescription drug coverage through a national formulary with no copays or deductibles; all Health Canada approved drugs would be reimbursed; and the process for reviewing drugs' clinical effectiveness would be fully transparent. However, it also notes some challenges with implementing this vision, including uncertainty around timely access to new drugs given the lengthy review process, the need to account for provincial healthcare priorities in a national formulary, and insufficient public funding requiring alternative sources and mechanisms to ensure access to necessary medications like cancer drugs.
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
The document discusses discordance between recommendations from the pan-Canadian Oncology Drug Review (pERC) and provincial funding decisions for cancer drugs in Canada. It presents results from a survey of provincial drug funding decision-makers that identified several potential reasons for discordance, including differences in priorities, clinical evidence, and budget constraints between the levels. Challenges to alignment included issues with clinical trial evidence as well as pressure to expand access, while suggested solutions centered on strengthening consensus around treatment pathways and priorities nationally.
Rare disease caucus
This document summarizes key provisions in the FDA Safety and Innovation Act (FDASIA) related to rare diseases. It discusses how FDASIA provides expedited pathways for drug and device approval for serious or life-threatening rare diseases through accelerated approval and breakthrough therapy designation. It also covers provisions around external experts, patient-focused drug development, rare pediatric disease priority review vouchers, guidance development, and changes to humanitarian device exemptions. The overall goal of these FDASIA provisions is to facilitate and encourage development of new therapies for rare and pediatric rare diseases.
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
The document discusses Canada's orphan drug regulatory framework and opportunities to improve access to rare disease drugs across Canada. It advocates for a life-cycle approach and managed access schemes where drugs are approved with evidence collection requirements. Traditional health technology assessment limits orphan drug access by rejecting drugs that are not cost-effective based on small clinical trials. The document recommends performance-based managed access programs with national guidelines and risk-sharing between provinces, patients, and companies to improve access while collecting long-term evidence on benefits, harms, and costs.STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
A Rare International Dialogue (Saturday May 11, 2019)
Ethnic and Diversity Issues
Inclusion in Clinical Trials - Jeff Keefer, IQVIA
How Will My Organization Absorb the Influx of New Patients? – Telehealth Cras...
How Will My Organization Absorb the Influx of New Patients? – Telehealth Cras...Epstein Becker Green
The implementation of the Affordable Care Act (“ACA”) has forced U.S. health care organizations to think about how best to position themselves to take advantage of such a massive change. It has been estimated that the ACA will expand coverage to approximately 32 million individuals lawfully present in the United States. At the same time, the United States’ rapidly increasing aging population will account for an additional 15 more million seniors covered by Medicare. This incredible influx of elderly and newly insured patients is forcing an already overly burdened U.S. health care system to utilize and implement policies to adequately handle this expanded patient population. But how will health care organizations absorb this radical increase in potential patients? Many are exploring telehealth/telemedicine options as an integral component of their treatment paradigm. They also need to address where the additional health care professionals will come from if the United States is not producing sufficient numbers.
In the final installment of EBG’s Telehealth Crash Course series, we will explore the potential health care immigration issues that employers should be aware of, as well as immigrant options that are available to help health care organizations recruit the foreign talent required to keep pace with a changing landscape.
Epstein Becker Green Webinar - Presented by Kimberly N. Grant
http://www.ebglaw.com/kimberly-n-grant/events/how-will-my-organization-absorb-the-influx-of-new-patients-telehealth-crash-course-webinar-series/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.Do States Like Telehealth? – Telehealth Crash Course Webinar Series
Telehealth has gone mainstream. As technology becomes more sophisticated and clinicians find innovative ways to provide services, the various applications of telehealth are taking on new dimensions. The trend toward telehealth is being driven by employers, private insurers, clinicians, and technology companies. The trend notwithstanding, serious legal and regulatory issues remain and will be a barrier to the wider adoption of telehealth. With the significant attention that recent litigation and enforcement activities in certain states have received, many view state laws and policies as the biggest impediment to the wider adoption of telehealth.
In the second installment of EBG’s Telehealth Crash Course series, we will discuss recent legal and regulatory developments in the states related to telehealth and the various initiatives underway to facilitate greater adoption of telehealth. Additionally, we will address issues such as multistate provider licensure, scope of practice, prescribing, and recently introduced state telehealth-related bills.
Epstein Becker Green Webinar - Presented by Rene Quashie on 9/15/2015.
http://www.ebglaw.com/ren%C3%A9-y-quashie/events/do-states-like-telehealth-telehealth-crash-course-webinar-series/
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
What's hot (20)
2018 opioid epidemic and its effect on texas hospitals ppt
2018 opioid epidemic and its effect on texas hospitals ppt
Challenges and Innovation in Canadian Access to Treatments and Innovation
Challenges and Innovation in Canadian Access to Treatments and Innovation
Webinar: Healthcare in the Federal Budget and How It May Affect Patients
Webinar: Healthcare in the Federal Budget and How It May Affect Patients
Cadth 2015 c6 panel collab formulary hospital-public plan - eric lun final
Cadth 2015 c6 panel collab formulary hospital-public plan - eric lun final
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Managing Value for Sponsors and Users in Public and Private Drug Plans: Angie...
Private Insurance Plans - Do they have a future in Canada?
Private Insurance Plans - Do they have a future in Canada?
Examining Models for a National Pharmacare Program
Examining Models for a National Pharmacare Program
How patient groups can have more say in the drug approval process
How patient groups can have more say in the drug approval process
Access to Drugs for Rare Diseases in Canada - April 2014
Access to Drugs for Rare Diseases in Canada - April 2014
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
STREAM THREE: Jeff Keefer, Inclusion in Clinical Trials
How Will My Organization Absorb the Influx of New Patients? – Telehealth Cras...
How Will My Organization Absorb the Influx of New Patients? – Telehealth Cras...
Do States Like Telehealth? – Telehealth Crash Course Webinar Series
Do States Like Telehealth? – Telehealth Crash Course Webinar Series
Viewers also liked
Cadth 2015 c5 2. lacaze cadth symposium 2015 powerpoint
MICYRN is a Canadian non-profit organization established in 2011 to reduce barriers and duplication of effort in multi-jurisdictional pediatric research, particularly for rare diseases. Rare diseases affect over 2.7 million Canadians but each affects fewer than 2000 individuals. MICYRN works to improve diagnosis of rare diseases and develop new therapies through national research networks and collaborating in international research initiatives. MICYRN also supports patient registries and clinical trials infrastructure to study rare diseases and determine drug safety and effectiveness in children through its research informatics platform and partnerships with health organizations and industry.
Cadth 2015 c5 4. harkins.cadth.symposium.2015
1) The document discusses the journey of patient advocate Kirsten Harkins and her son Nicklas who was diagnosed with MPS I.
2) It describes some of the early challenges in advocating for funding and access to treatments for rare diseases in Canada.
3) Key to success has been collaboration between patient advocacy groups, health ministries, and other stakeholders to work towards more meaningful patient involvement in research, treatment evaluation, and healthcare policy decisions impacting rare disease patients.
Cadth 2015 c5 1. cashman rare diseases
The document discusses neurodegenerative diseases that are caused by the misfolding and aggregation of proteins, including Alzheimer's disease, Parkinson's disease, ALS, and prion diseases. It describes how antibodies can selectively target misfolded proteins causing disease while sparing native protein structures, providing efficacy through neutralizing toxicity and blocking propagation while maintaining safety by preserving normal function. The document also provides an overview of an assay to quantify aggregated amyloid beta and lists several propagated protein misfolding diseases.
Cadth 2015 a1 (gs090315)
This document summarizes preliminary results from modeling screening and treatment pathways for diabetic retinopathy in Scotland. The model finds that annual screening may not be cost-effective for individuals with a 1-year risk of progression below 1%, suggesting biennial screening could reduce costs with minimal quality-adjusted life year losses. Around 55% of the current annual screening cohort has such low risk. Further analysis is needed to characterize uncertainty and evaluate alternative screening and treatment configurations. The pathway modeling provides a framework to inform changes over time but has challenges around uncertainties and validation.
Cadth 2015 c6 symposiuml semchuk the rqhr perspective
This document discusses opportunities for increased collaboration across formularies in Saskatchewan's health regions. It provides context on the current decision-making processes and formularies within the Regina Qu'Appelle Health Region. Challenges include differences in coverage of drugs between regions that can impact patients who transfer between facilities. Greater alignment is needed, as demonstrated by a successful example of a provincial working group that aligned ticagrelor coverage based on clinical evidence. Overall, the speaker argues that formalizing collaboration through initiatives like joint evidence reviews and policy consultation can help standardize practices across regions to improve patient care continuity.
Cadth 2015 a1 panel1
This document discusses the development of the Evaluation Platform in COPD (EPIC) model. The model aims to evaluate COPD case detection strategies and their impact on outcomes like costs and quality of life. It uses a whole disease modeling approach with discrete event simulation to model the natural history of COPD. Evidence from studies like the Lung Health Study will be synthesized to model disease progression markers like FEV1 decline over time. The model will be calibrated against data sources and engaged stakeholders to ensure it is useful for evaluating COPD policies and guidelines. The challenges include gaining meaningful clinical input and ensuring sustainability, but the conceptual framework is expected to further understanding of COPD and allow flexible evaluation of different research questions.
Cadth 2015 c6 faith louis cadth panel discussion april 2015
This document summarizes New Brunswick's experience collaborating on a provincial hospital formulary. Key points include:
- New Brunswick has 2 regional health authorities serving a population of 754,524 across 22 hospitals.
- In 2010, New Brunswick launched a single provincial Drugs and Therapeutics committee with representation from both health authorities to create a universal provincial hospital formulary.
- The committee considers evidence-based evaluations and aims to provide seamless care between hospitals and continuity between hospital and community care.
- Opportunities include greater alignment between hospital and outpatient drug programs and better resource use. Challenges include differences between hospital and community care.
Cadth 2015 a5 3 cadth panel pauline mc nulty april 2015 no notes
This document discusses the increasing role of patients in drug development and healthcare decision making. It notes that patients want a greater voice in deciding what evidence is required to show drug effectiveness, influencing clinical trial design, and assessing risk/benefit for regulatory approval. PROs (patient-reported outcome measures) are highlighted as a way to systematically capture the patient perspective on symptoms, functioning and quality of life in clinical trials and practice. The example shows how PRO data from rheumatoid arthritis trials demonstrated improvement in daily activities with certain drug treatments.
Cadth 2015 c5 3. d. whiteman
This document discusses definitions of rare diseases and considerations for drug development in rare diseases. It notes that rare diseases are defined differently in various regions but generally refer to diseases affecting fewer than 5 in 10,000 people in Canada, 1 in 2,000 in Europe, 50,000 in Japan, and 200,000 in the US. However, cumulatively over all rare disease families, about 1 in 12 people are affected by a rare disease. The document outlines challenges in rare disease drug development including small patient populations, lack of natural history data and treatment guidelines, need for alternative clinical trial designs, and difficulties detecting adverse events. It emphasizes the need to involve patients, families, regulators early in the process and consider broader views of value
Cadth 2015 a5 5 cadth symposium 2015 - laura faye
This document discusses a presentation on collecting patient-reported outcome measures (PROMs) routinely in Canada. The objectives of the presentation were to achieve a shared understanding of PROMs and how they can support health system goals, discuss considerations for a common approach to PROMs collection and use, and assess interest in standardized collection. It provides examples of PROMs collection in different jurisdictions and highlights priorities and barriers to wider adoption in Canada. These include engaging clinicians, defining the purpose, and having jurisdictional support. There was strong interest in forming a working group and pilot projects to advance standardized PROMs collection across Canada.
Cadth 2015 b3 rapid reviews oral presentation cadth_11_apr2015
This document summarizes the results of a research program on rapid reviews. It presents findings from a scoping review, international survey, and consensus-building exercise regarding rapid review methods. The scoping review found numerous rapid review approaches with little consistency. The survey found that rapid reviews are usually conducted within 12 weeks for government agencies. The consensus exercise reached agreement on Approach 1 as the highest ranked method to test in a prospective diagnostic study comparing rapid reviews to systematic reviews. The overall goal is to identify the most accurate and feasible rapid review methods.
Cadth 2015 e5 ad panel discussion af
The document discusses guidelines from different committees on oral anticoagulants for atrial fibrillation stroke prevention that show some discordance despite being based on the same three landmark trials. It suggests that values influence guideline committees and prescribing specialists differently, and that patient values through shared decision making should also be considered to tailor therapy to individual patients.
Cadth 2015 b5 cadth presentation francois dionne fa
This document outlines initial steps taken to develop a multi-criteria approach for drug reimbursement decisions. It summarizes work done through two workshops involving key stakeholders to identify guiding principles and criteria for consideration. Ten criteria were identified, and next steps include finalizing criteria selection, refining definitions, setting weights, developing rating scales, and testing the completed framework. The goal is to evolve decision making to consider additional factors beyond just cost-effectiveness.
Cadth 2015 a2 cadth symposium2015 panel_valuingmedicaltech_13april2015_clessard
Chantale Lessard discusses key differences between medical devices and pharmaceuticals that impact health technology assessment (HTA). She notes that a "one-size-fits-all" approach to HTA is inappropriate given differences in devices' types, contexts of use, and indications. HTA for devices should be tailored and viewed as iterative, considering clinical efficacy, cost-effectiveness, and also social, ethical, and organizational implications. Developing innovative HTA methods for devices requires engagement from industry and decision-makers.
Cadth 2015 b5 symposium oral - cost-drivers in public drug plans in canada
This document summarizes a report on the cost drivers of public drug plans in Canada from 2012-2013. It finds that while demographic and usage trends pushed drug costs up, cost savings from generic substitution and lower generic drug prices nearly offset these increases, keeping the overall drug cost growth low. Specifically, demographic and higher usage trends would have increased costs by 8.5% without generic savings, while greater generic usage and lower prices decreased costs by 9.2%. The report also examines factors driving increases in dispensing fees, finding prescription size reductions contributed to higher costs for some plans. Future reports will continue monitoring cost drivers in public drug plans.
Cadth 2015 d7 burgess cadth 2015 20150414
This document discusses different forms of public engagement that could be appropriate for drug policy decisions. It notes that deliberative public engagement events can incorporate diverse perspectives but may not be fully representative. It advocates for participatory governance with advisory bodies that regularly refresh their engagement to better reflect the public. Experiments with different engagement methods should be assessed to help balance input with decision efficiency.
Buzz network (1) copy
This document provides an overview of buzz networking and social media marketing. It defines buzz networking as creating excitement about a product through online marketing. Social media marketing utilizes social media platforms as a marketing tool to create buzz and spread content that users will share, increasing brand exposure. The document outlines various social media platforms like Facebook, Twitter, LinkedIn and YouTube and how they can be used for social media marketing. It also discusses advantages like increased traffic, disadvantages like decreased productivity and interactive marketing strategies like viral marketing and pop-up ads. A case study shows how Samsung used social media for customer support. A survey found most people are aware of and interested in learning more about buzz networking and social media marketing.
Vulcânismo Secundário
O documento discute o vulcanismo secundário, incluindo fumarolas, géisers e nascentes termais. Também descreve métodos de monitoramento vulcânico como recolha de gases, lava e registos sísmicos. Finalmente, destaca usos benéficos da atividade vulcânica como fertilização de solos, construção, energia geotérmica e turismo.
Document
Este documento presenta la planificación didáctica de un módulo formativo sobre selección, elaboración y utilización de materiales didácticos en formación profesional. El módulo tiene una duración de 90 horas y se enmarca dentro de un plan de formación de la Comunidad de Madrid. La planificación incluye la justificación, objetivos, contenidos, metodología, actividades, recursos y sistema de evaluación. El objetivo general es que los alumnos sean capaces de seleccionar, elaborar, adaptar y utilizar materiales didá
Viewers also liked (20)
Cadth 2015 c5 2. lacaze cadth symposium 2015 powerpoint
Cadth 2015 c5 2. lacaze cadth symposium 2015 powerpoint
Cadth 2015 c6 symposiuml semchuk the rqhr perspective
Cadth 2015 c6 symposiuml semchuk the rqhr perspective
Cadth 2015 c6 faith louis cadth panel discussion april 2015
Cadth 2015 c6 faith louis cadth panel discussion april 2015
Cadth 2015 a5 3 cadth panel pauline mc nulty april 2015 no notes
Cadth 2015 a5 3 cadth panel pauline mc nulty april 2015 no notes
Cadth 2015 b3 rapid reviews oral presentation cadth_11_apr2015
Cadth 2015 b3 rapid reviews oral presentation cadth_11_apr2015
Cadth 2015 b5 cadth presentation francois dionne fa
Cadth 2015 b5 cadth presentation francois dionne fa
Cadth 2015 a2 cadth symposium2015 panel_valuingmedicaltech_13april2015_clessard
Cadth 2015 a2 cadth symposium2015 panel_valuingmedicaltech_13april2015_clessard
Cadth 2015 b5 symposium oral - cost-drivers in public drug plans in canada
Cadth 2015 b5 symposium oral - cost-drivers in public drug plans in canada
Similar to Cadth 2015 c6 final exploring opportunities for collaboration across the spectrum of
Cadth 2015 c6 final- hospital formularies decision-making process es
This document summarizes the findings of a survey on collaboration between hospital formulary decision-making committees and provincial public drug plans in Canada. The survey found that most respondents considered public drug plan formulary recommendations in their decisions. While some provinces have formal policies for alignment, others have informal processes. Challenges to alignment include differences in institutional roles and factors considered, as well as decision-making processes, implementation issues, and product types under review. Overall the survey identified ongoing efforts across Canada to improve collaboration and consistency between hospital and public drug plan formularies.
Patient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submissionCanadian Organization for Rare Disorders
This document summarizes a presentation given by Maureen Smith on patient involvement in drug coverage reviews in Ontario. It outlines how patient groups can submit evidence to be considered by the Committee to Evaluate Drugs, including registering as a patient group, using the submission template, and meeting submission deadlines. It also provides suggestions for making submissions more impactful, such as prioritizing the most important impacts of a disease and treatment outcomes. The goal is to systematically incorporate the patient perspective into drug review and funding decisions in Ontario.Law update, march 2011
This document summarizes recent legal issues affecting the practice of pharmacy in North Carolina. It discusses proposed state bills on pharmacy technician responsibilities in hospitals and pharmacist vaccination authority. It also outlines recent statutes on drug donation programs and upcoming elections for the North Carolina Board of Pharmacy.
Tuesday astho
The document summarizes a vision session on prescription opioid overdose that included presentations from the Oklahoma Commissioner of Health and the president of ASTHO. Key points discussed include:
- The growing epidemic of prescription opioid overdose deaths and costs to the healthcare system.
- ASTHO's Prescription Drug Overdose Prevention Challenge which aims to reduce overdose rates and engages state health officials and partners across sectors.
- Strategies discussed to address the epidemic through prevention, monitoring, enforcement, treatment and recovery efforts.
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Primer for attendees attending the November 15-16 Drug Pricing Policy Summit
● Broad conceptual blueprint of federal and provincial/territorial public health policy structures across Canada
● Description of legal frameworks, government responsibility centres and their mandates for treatment access, with reference to specific opportunities for patient engagement
View the video: https://youtu.be/X9AB70om-Dw
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Pharmacare - Caveat Emptor (Let the Buyer Beware)
The document outlines a discussion on developing a universal pharmacare program in Canada, including reviewing different models proposed, lessons from international programs, and perspectives from mental health advocates. A vision and principles for a potential universal pharmacare plan are proposed that emphasize equitable access to necessary medications for all Canadians through a publicly-funded program. Next steps discussed include finalizing a report and seeking opportunities to promote the proposed approach.
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...Emmanuel Mosoti Machani
Dr. Julius Ogato was aming the Ministry of Health Departmental Heads presenting at the 3rd HSDPF.
The presentation elicited interest from counties keen on adopting a single-use policy for health products and commodities. Rx15 tpp tues_1230_allen-emptage
This document summarizes a presentation on legislative and medication trends impacting third-party payers. It discusses several topics: physician dispensing and repackaged medications, opioid utilization, treatment guidelines and closed formularies, and compounded medications. For each topic, it outlines related legislative strategies and regulatory approaches taken by different states to influence costs and utilization for third-party payers. The presentation aims to identify issues relevant to third-party payers and explain how they can shape legislative and regulatory outcomes.
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
How Medication Adherence and Specialty Drugs Impact Employer Healthcare CostsHEALTHWORKS by Carolinas Healthcare System
This Atrium Health study and pilot program revealed healthcare savings potential resulting from a tailored approach to medication adherence and specialty drug programs.
CDC Initiatives & Priorities to Address the Prescription Drug Overdose Crisis...
CDC Initiatives & Priorities to Address the Prescription Drug Overdose Crisis...University of Michigan Injury Center
Presentation delivered at the University of Michigan Injury Center Opioid Overdose Summit, Ann Arbor, MI, December 1, 2015The Orphan Drug Act
The document summarizes the Orphan Drug Act of 1983 and its impact. It provides incentives like 7 years of marketing exclusivity and tax credits to stimulate development of drugs for rare diseases defined as affecting fewer than 200,000 people. Since 1983, over 1000 designations and 200 product approvals have occurred. While the Act has met its objectives, concerns around the high costs of orphan drugs and determining appropriate access and reimbursement are discussed.
Health Information Technology, Quality Improvement, and the Delivery System R...
Maryland has established a "phalanx" strategy to coordinate implementation of health IT, quality improvement initiatives, and delivery system reforms. The phalanx involves a large number of stakeholders working together, with leadership serving on the front line to push initiatives forward. While linking payment to quality and changing hospital payments will face challenges, having many groups collaborating and supporting each other can help drive changes through. The state has made progress in areas like establishing a health information exchange, adopting electronic health records, and developing medical home pilots. Fully achieving reforms will require maintaining stakeholder cooperation and momentum.
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
This document summarizes a presentation on insights from state policies and interventions to curb prescription drug overdoses. It describes several interventions:
1) PRIMUM, a system in North Carolina that alerts prescribers to patients' risk of misusing or abusing opioids at the point of care.
2) A project in Rhode Island that developed protocols to improve opioid prescription safety for trauma patients, including alerts if prescriptions exceed dosage thresholds and requiring naloxone co-prescriptions.
3) A study in Pennsylvania that used Medicaid claims data to identify risk factors for opioid overdoses, such as high dosage and multiple prescribers/pharmacies, to target high-risk patients.
Trudel cms-rules-072810[1]
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
HIT Standards Committee Trudel CMS Rules
The document discusses changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program. Key changes included clarifying provider eligibility, modifying clinical quality measures, and lowering thresholds for some meaningful use objectives. The final rule kept the same statutory requirements and meaningful use goals as the proposed rule.
Trudel Cms Rules 072810[1]
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures requirements for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting policies to fully implement the program in 2011.
Trudel cms-rules-072810[1]
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
Trudel Cms Rules 072810[1]
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
Trudel cms-rules-072810[1]
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
Trudel Cms Rules 072810[1]
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
Similar to Cadth 2015 c6 final exploring opportunities for collaboration across the spectrum of (20)
Cadth 2015 c6 final- hospital formularies decision-making process es
Cadth 2015 c6 final- hospital formularies decision-making process es
Patient Input: What is asked for and what is helpful in a patient submission
Patient Input: What is asked for and what is helpful in a patient submission
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Drug Approval Bodies in Canada 101: The Elevator Length Pitch
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...
Health products and technologies Dr. Julius Ogato, Ministry of Health. Head...
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
How Medication Adherence and Specialty Drugs Impact Employer Healthcare Costs
CDC Initiatives & Priorities to Address the Prescription Drug Overdose Crisis...
CDC Initiatives & Priorities to Address the Prescription Drug Overdose Crisis...
Health Information Technology, Quality Improvement, and the Delivery System R...
Health Information Technology, Quality Improvement, and the Delivery System R...
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
More from CADTH Symposium
Cadth symp breakfast 4 Update to Guidelines for the Economic Evaluation of He...
This document provides details about an update to the 3rd edition of CADTH's Guidelines for the Economic Evaluation of Health Technologies in Canada. It discusses that the methodology for economic evaluations is constantly evolving so it is important to provide up-to-date guidance. Key points include that CADTH and a working group are leading the update, topics from the 3rd edition will be reviewed and some identified for updates, new topics will be added, and stakeholders will provide feedback on gaps and challenges. Milestones include discussion sessions in 2015/2016 and posting a revised 4th edition for feedback in Spring 2016.
Cadth 2015 e1 deal prader willi cadth
This document summarizes a workshop on developing clinical care guidelines for growth hormone treatment in Prader-Willi syndrome. The workshop brought together over 40 experts, including endocrinologists, geneticists, clinicians with an interest in growth hormone research, patient advocates, and methodologists. It utilized a multi-criteria decision analysis framework to develop the guidelines, taking into account scientific evidence, disease impact, safety, and other criteria. The goal was to produce consensus guidelines that integrated evidence, values, and ethics to guide policy and clinical practice around this complex treatment decision.
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2
The document summarizes a literature review examining decision-making methodologies used in health technology appraisal processes. It describes common decision criteria identified in the literature, including efficacy, safety, disease burden, quality of evidence, ethics and cost-effectiveness. Decision-making methods reviewed integrate these criteria through approaches like assigning weights, ranking criteria or using decision rules. The literature search included publications from organizations in several countries.
Cadth 2015 e3 eq5 d
This document describes a study that used a discrete choice experiment with duration (DCEtto) to value health states described by the EQ-5D-5L instrument in Canada. It notes limitations of the traditional time trade-off (TTO) method, such as many respondents not understanding or engaging with the task. The study found the DCEtto method led to fewer exclusions, increasing representativeness. Health state values from the DCEtto were generally lower than the TTO but allowed valuing all respondents. The document discusses differences in the distributions and average levels of values from the two methods and impact of exclusions. It acknowledges limitations to interpreting DCEtto values that require further investigation.
Cadth 2015 e6 husereau rwe cadth
The document summarizes discussions from two roundtables on opportunities and barriers to using real-world evidence in Canada. Key points identified include the need to: 1) build a culture that recognizes real-world evidence can foster healthcare innovation; 2) increase understanding of real-world evidence's value to improve quality and efficiency; and 3) use common data structures and vocabularies to better link and analyze data. Next steps discussed building real-world evidence capacity in Canada through continued stakeholder discussions, leveraging existing data infrastructure, and balancing privacy concerns with the need for appropriate care.
Cadth 2015 e4 lourenco adaptive design april 2015 final
Health Canada regulates clinical trials and drug approvals. Adaptive clinical trial designs are increasing and can modify aspects of ongoing trials using accumulating data. Health Canada's main concerns are appropriate scientific questions, error control, and avoiding bias. Examples seen include adaptive randomization, sample size changes, and seamless phase 2/3 designs. Case studies demonstrate increased complexity, new statistical methods, and more simulation use. Health Canada recommends early consultation and education on adaptive designs.
Cadth 2015 e4 fields slides for adaptive panel final
This document discusses pCODR's experience with adaptive clinical trial designs and how they impact drug funding assessments. It provides examples of two clinical trials for chronic lymphocytic leukemia (CLL) and non-small cell lung cancer (NSCLC) that used adaptive designs. The CLL trial had early stopping rules and treatment switching based on interim analyses. The NSCLC trial allowed patients who progressed on chemotherapy to switch to the experimental drug crizotinib, introducing uncertainty into estimating the treatment's effectiveness and cost-effectiveness. pCODR will likely see more complex adaptive designs as cancer treatments increasingly target biomarker-defined subgroups and employ personalized medicine approaches, requiring continuous evolution of its assessment expertise.
Cadth 2015 e4 mcelwee cadth 041415 fnl
This document discusses adaptive clinical trial designs used by Merck for oncology studies. It provides examples of different types of adaptive designs including:
1) Dose-finding designs like modified toxicity profile interval designs that allow for dose escalation and de-escalation in a table-driven manner.
2) Single-arm response rate studies that can provide early access for patients and allow early interim analyses to discontinue biomarker-negative patient populations if no responses are found.
3) Comparative studies with dual primary endpoints of overall survival and progression-free survival that can adapt based on biomarker-selected patient populations at interim analyses.
4) Bayesian adaptive studies like I-SPY 2 that
Cadth 2015 e4 thorlund innovative trial designs in medical decision making
Adaptive clinical trial designs are increasingly used in commercial trials due to demands for faster evidence and more efficient trials. However, health technology assessment decision-making typically requires large parallel randomized controlled trials, creating a mismatch. Without long-term placebo/control data or trials that resemble approved treatment algorithms, innovative trial designs risk not providing sufficient evidence for reimbursement decisions. To address this, more education is needed on innovative designs for health technology assessors, and trials should apply these designs to further validate their ability to provide robust evidence for reimbursement.
Cadth 2015 e1 2015 04 cadth v2.0
This document summarizes a panel discussion on integrating evidence, values and ethics into healthcare decision-making using multicriteria decision analysis (MCDA). It discusses how MCDA can help address ethical dilemmas by explicitly considering multiple criteria, including efficacy, safety, costs, and other social values. It outlines the key steps in MCDA, including defining objectives and criteria, assigning weights to criteria, synthesizing evidence on the criteria, scoring performance on criteria, and aggregating scores to determine the overall value of interventions. The document emphasizes that MCDA supports making decisions in a way that is participatory, transparent, systematic and reflective of different stakeholder perspectives to arrive at decisions that optimize health in its widest sense.
Cadth 2015 e4 adaptive design april 2015 final lourenco
Health Canada regulates clinical trials and drug approvals. Adaptive clinical trial designs are increasing and can modify aspects of ongoing trials using accumulating data. Health Canada's main concerns are appropriate scientific questions, error control, and avoiding bias. Examples seen include adaptive randomization, sample size changes, and seamless phase 2/3 designs. Case studies demonstrate increased complexity, new statistical methods, and more simulation use. Health Canada recommends early consultation and education on adaptive designs.
Cadth symposium 2015 d3 pr os va. generic measures cadth 14th april 2015
This document discusses the use of generic and condition-specific patient-reported outcome measures (PROs) in value-based healthcare reimbursement decisions. It compares the EQ-5D-3L generic PRO to the PuQol_UI condition-specific PRO for pressure ulcers. The condition-specific measure was more sensitive to pressure ulcer severity levels compared to the generic measure. Using different PROs can lead to different assessments of treatment value and impact reimbursement decisions. The document concludes that using PROs in reimbursement requires care, as it can impede equitable decision-making and comparing "apples to oranges" treatments.
Cadth 2015 d5 symposium 2015 endonodal trials - version 2
This document discusses methods for incorporating single-arm study data into network meta-analyses (NMAs). Currently, NMAs primarily use data from randomized controlled trials. The document presents two methods for including single-arm evidence: 1) Using single-arm results to create informative priors in Bayesian NMA models, and 2) Creating "virtual comparisons" based on patient characteristics to include single-arm studies directly in the NMA. It provides examples applying these methods in analyses of treatments for cryptococcal meningitis and hepatitis C. The results showed inclusion of single-arm evidence can improve model fit and precision of treatment effect estimates in NMAs.
Cadth 2015 e5 noac ad symposium_panel_14apr2015
This document summarizes a symposium on promoting evidence-based use of anticoagulants across Canada. It discusses the prevalence of atrial fibrillation, options for anticoagulation including warfarin and newer oral anticoagulants, and initiatives for collaboration between provinces to educate health professionals and patients on appropriate anticoagulant therapy. Speakers from various provinces outlined academic detailing programs and a CADTH systematic review comparing benefits and harms of anticoagulants.
Cadth 2015 breakfast 2 excel hta tools presentation final
The document provides an overview of CADTH Excel-based health technology assessment tools that have been developed or are in development. It summarizes NetMetaXL, an Excel-based tool for conducting network meta-analyses of dichotomous outcomes. The presentation includes a live demo of NetMetaXL and previews of three other CADTH Excel-based HTA tools.
Cadth 2015 d7 presentation 2015 14 apr15
This document presents a framework for strengthening public and patient engagement in Health Quality Ontario's evidence review process. Key elements of the framework include articulating goals and principles, establishing a common language, describing a menu of engagement approaches matched to process stages, and identifying measures. The framework was developed through a review of literature and practices, expert consultation, and stakeholder dialogue. It recommends increasing transparency, incorporating diverse perspectives throughout stages, and evaluating engagement impacts. The framework provides guidance to enhance public and patient contributions to health technology decision-making in Ontario.
Cadth 2015 d4 lidia engel final
This document discusses challenges associated with going beyond health-related quality of life measures in cost-utility analysis. It notes that while economic evaluations often use quality-adjusted life years (QALYs) based on health-related quality of life instruments like EQ-5D, interventions can provide benefits beyond health alone. There are theoretical, normative, conceptual and methodological challenges to incorporating these broader outcomes. Measuring instruments have been developed to capture non-health domains, but valuing these outcomes poses challenges. Considering non-health outcomes increases complexity, but may provide a more comprehensive assessment.
Cadth 2015 d2 procurement oral presentation-vf
This document discusses the relationship between health technology assessment (HTA) and healthcare procurement in supporting appropriate use of health technologies. While HTA and procurement share roles in patient outcomes, quality and cost, they differ in their processes and criteria. HTA focuses on evidence-based clinical and cost-effectiveness while procurement adjudicates fair competitive bidding processes. The document analyzes how HTA and procurement are articulated in four Canadian provinces, finding early efforts to connect them formally but disjuncture in their evaluative frameworks. It concludes that both fields could learn from each other to better support comprehensive technology management and value-based decision making.
Cadth 2015 d6 rn np cadth srna (2)
This document discusses the implementation and impact of adding a nurse practitioner (NP) to the staff at a long-term care facility based on the Eden Philosophy. The Eden Philosophy aims to eliminate loneliness, helplessness, and boredom for long-term care residents. Adding an NP aligned with the facility's vision to provide timely access to primary care. Research shows NPs in long-term care can increase family satisfaction and access to health services. As an onsite provider, the NP is able to closely monitor residents and help reduce factors like falls, antipsychotic use, and hospital admissions by optimizing medications. Outcomes data also shows reductions in pain levels, pressure ulcers, and prescription burden with the involvement of an NP
Cadth 2015 e2 miller cadth-ohtac approach-april 14, 2015
This document discusses improving how non-drug technologies are appraised in Ontario by revising the decision-making framework. It summarizes work done by various committees and working groups since 2007 to operationalize ethics and social values in the appraisal process. This includes identifying core social values, developing evaluative questions related to equity, patient-centered care and other domains, and proposing a methodology for systematic, evidence-based analysis of ethics and social values issues. The goal is to fully integrate such analyses into the technology appraisal process to make recommendations more responsive to patient and societal considerations.
More from CADTH Symposium (20)
Cadth symp breakfast 4 Update to Guidelines for the Economic Evaluation of He...
Cadth symp breakfast 4 Update to Guidelines for the Economic Evaluation of He...
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2
Cadth 2015 e4 lourenco adaptive design april 2015 final
Cadth 2015 e4 lourenco adaptive design april 2015 final
Cadth 2015 e4 fields slides for adaptive panel final
Cadth 2015 e4 fields slides for adaptive panel final
Cadth 2015 e4 thorlund innovative trial designs in medical decision making
Cadth 2015 e4 thorlund innovative trial designs in medical decision making
Cadth 2015 e4 adaptive design april 2015 final lourenco
Cadth 2015 e4 adaptive design april 2015 final lourenco
Cadth symposium 2015 d3 pr os va. generic measures cadth 14th april 2015
Cadth symposium 2015 d3 pr os va. generic measures cadth 14th april 2015
Cadth 2015 d5 symposium 2015 endonodal trials - version 2
Cadth 2015 d5 symposium 2015 endonodal trials - version 2
Cadth 2015 breakfast 2 excel hta tools presentation final
Cadth 2015 breakfast 2 excel hta tools presentation final
Cadth 2015 e2 miller cadth-ohtac approach-april 14, 2015
Cadth 2015 e2 miller cadth-ohtac approach-april 14, 2015
Recently uploaded
What is Obesity? How to overcome Obesity?
Obesity is a chronic complex disease defined by excessive fat deposits that can impair health.
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
This document outlines policies and procedures for handling narcotic and controlled drugs in NABH accredited hospitals.
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
5 Effective Homeopathic Medicines for Irregular Periods
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Nano-gold for Cancer Therapy chemistry investigatory project
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort. Dr. Tan's Balance Method.pdf (From Academy of Oriental Medicine at Austin)
Home
Organization
Academy of Oriental Medicine at Austin
Academy of Oriental Medicine at Austin
Academy of Oriental Medicine at Austin
About AOMA: The Academy of Oriental Medicine at Austin offers a masters-level graduate program in acupuncture and Oriental medicine, preparing its students for careers as skilled, professional practitioners. AOMA is known for its internationally recognized faculty, award-winning student clinical internship program, and herbal medicine program. Since its founding in 1993, AOMA has grown rapidly in size and reputation, drawing students from around the nation and faculty from around the world. AOMA also conducts more than 20,000 patient visits annually in its student and professional clinics. AOMA collaborates with Western healthcare institutions including the Seton Family of Hospitals, and gives back to the community through partnerships with nonprofit organizations and by providing free and reduced price treatments to people who cannot afford them. The Academy of Oriental Medicine at Austin is located at 2700 West Anderson Lane. AOMA also serves patients and retail customers at its south Austin location, 4701 West Gate Blvd. For more information see www.aoma.edu or call 512-492-303434.
Call Girls Lucknow 9024918724 Vip Call Girls Lucknow
Call Girls Lucknow 9024918724 Vip Call Girls Lucknow
PGx Analysis in VarSeq: A User’s Perspective
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
Pharmacology of 5-hydroxytryptamine and Antagonist
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
All about shoulder Joint ..
All about shoulder joint , Anatomy ,Examination, Special tests and radiology.
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Fallopian tube blockage may cause female infertility. For treatment, herbal medicine Fuyan Pill can be a solution.
Ageing, the Elderly, Gerontology and Public Health
Challenges associated with ageing from a public health perspective
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
Pharmacology of Drugs for Congestive Heart Failure
Congestive Heart failure is caused by low cardiac output and high sympathetic discharge. Diuretics reduce preload, ACE inhibitors lower afterload, beta blockers reduce sympathetic activity, and digitalis has inotropic effects. Newer medications target vasodilation and myosin activation to improve heart efficiency while lowering energy requirements. Combination therapy, following an assessment of cardiac function and volume status, is the most effective strategy to heart failure care.
Helminthiasis or Worm infestation in Children for Nursing students
Brief description worm infestation/Helminthiasis for Basic B.Sc Nursing students
Recently uploaded (20)
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
Call Girls In Mumbai +91-7426014248 High Profile Call Girl Mumbai
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Dr. Tan's Balance Method.pdf (From Academy of Oriental Medicine at Austin)
Dr. Tan's Balance Method.pdf (From Academy of Oriental Medicine at Austin)
Call Girls Lucknow 9024918724 Vip Call Girls Lucknow
Call Girls Lucknow 9024918724 Vip Call Girls Lucknow
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Pharmacology of Drugs for Congestive Heart Failure
Pharmacology of Drugs for Congestive Heart Failure
Helminthiasis or Worm infestation in Children for Nursing students
Helminthiasis or Worm infestation in Children for Nursing students
Cadth 2015 c6 final exploring opportunities for collaboration across the spectrum of
- 1. Anne Hiltz, Director Pharmacy and Renal Program Nova Scotia Health Authority
- 2. Speaker has no real or potential conflicts to disclose in relation to this presentation
- 3. Established April 1, 2015 as an amalgamation of nine previous health districts with over 23,000 employees and 2500 physicians Includes all health care organizations (acute, tertiary, quaternary, community, mental health, addictions, forensics) with the exception of the IWK Health Centre Comprised of four zones $94 million dollars in drug expenditures
- 4. Current state of transition with district drug formulary decision-making still in place Majority of presentation will focus on existing state within previous Capital District Health Authority, now Central Zone of Nova Scotia Health Authority
- 5. No mandate to align hospital formulary with provincial drug plan Good working relationship with Pharmacy Services, Department of Health and Wellness Commitment to focus on alignment
- 6. All formulary and drug policy decisions across the district (nine sites and roughly 50% of provincial population) approved at the District Drugs and Therapeutics Committee (DD&T), with the exception of newer oncology drugs approved by the province
- 7. On admission, patients kept on current medication even if non-formulary in hospital mainly for safety reasons and issues with medication reconciliation Drug reviews only initiated upon request of prescribers (e.g. levetiracetam)
- 8. Three types of reviews: Drugs on provincial formulary Drugs not on provincial formulary and hospital-only drugs High-cost non-formulary drugs
- 9. Budget impact analysis only completed and reviewed at DD&T If above a set dollar limit, request for funding goes to Executive
- 10. Complete review prepared by a subcommittee of DD&T in consultation with stakeholders Safety, efficacy and all elements of cost considered (e.g. IV irons) Both pharmacoeconomic and ethics expertise on DD&T Recommendations are taken to DD&T with the committee voting on the recommendations Excellent collaboration between different departments within hospital (e.g. NOAC’s)
- 11. Drug requested usually by a specialist to VP, Medicine Pharmacy reviews evidence (often limited) and makes recommendation to VP VP informs requestor of decision
- 12. Knowledge of committee members increased Willingness of most clinicians throughout organization to wait on provincial decision before submitting request (i.e. NOACs) Increased engagement in process Enabled by co-leadership model across organization
- 13. Eagerness to use all new drug entities in a tertiary care organization Perception that decisions made by both CADTH and the province are related mainly to cost and not efficacy Lack of depth of knowledge re: evidence informed decision-making by some individuals
- 14. Structure of DD&T in a provincial health authority? Will there will one single formulary for the province? How will all parts of the province be represented? Challenge of developing a single provincial hospital formulary with many smaller community hospitals while aligning it with the province, especially if not mandated